3-hydroxytamoxifen (droloxifene)

Subscribe to Selected New Research on 3-hydroxytamoxifen

62 relevant articles (5 outcomes, 17 trials/studies) found for this Bio-Agent

Also Known As:

droloxifene; 3-hydroxytamoxifen citrate; FK 435; FK-435; FK435; droloxifene citrate; meta-hydroxytamoxifen; Phenol, 3-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)-, (E)-

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 42

Hydrocarbons: 362

Cyclic Hydrocarbons: 3

Aromatic Hydrocarbons: 121

Benzene Derivatives: 9

Benzylidene Compounds

Stilbenes: 43

Tamoxifen: 8020

3-hydroxytamoxifen: 62

Experts

1.	Chen, Bao-An: 1 article (12/2005)
2.	Gao, Feng: 1 article (12/2005)
3.	Lu, Zu-Hong: 1 article (12/2005)
4.	Zhang, Chun-Xiu: 1 article (12/2005)
5.	Cheng, Jian: 1 article (12/2005)
6.	Du, Juan: 1 article (12/2005)
7.	Martin, J H J: 1 article (07/2003)
8.	Symonds, A: 1 article (07/2003)
9.	Chohan, S: 1 article (07/2003)
10.	Bi, Dong-Song: 1 article (04/2003)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/1994 - "A phase II study compared droloxifene in dosages of 20, 40, and 100 mg daily in postmenopausal women with metastatic, or inoperable recurrent, or primary locoregional breast cancer who had not received prior hormonal therapy. " 01/01/1994 - "Phase I trial of droloxifene in patients with metastatic breast cancer." 07/01/1993 - "[Treatment of advanced breast cancer in postmenopausal women with droloxifene: results of a double-blind phase II trial for dose determination]" 01/01/1992 - "Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial." 01/01/1991 - "Japanese early phase II study of droloxifene in the treatment of advanced breast cancer. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 09/15/1994 - "In vivo, Droloxifene displayed increased growth inhibition of different tumors of animal (R3230AC and 13762) and human origin (T61). " 09/15/1994 - "As another consequence of the high stability of the complex formed by Droloxifene binding to the ER, intermittent exposures with clinically relevant concentrations of Droloxifene brought about effective growth inhibition of human ER positive tumor cells even after short-term application. " 09/01/1993 - "The estrogenic and antiestrogenic activities of droloxifene in human breast cancers." 09/14/1992 - "This mechanism may be related to the clinically important antiproliferative action of droloxifene on cancer cells." 09/14/1992 - "This inhibition of lipid peroxidation by droloxifene may result from a membrane stabilization that could be associated in cancer cells with decreased plasma membrane fluidity. " Order ALL the reference details at left...
3.	Disease Progression 05/01/2002 - "RESULTS: The hazard ratio (droloxifene/tamoxifen) for the primary endpoint, time to disease progression, was 1.287 favoring tamoxifen (95% C.I.: 1.114-1.487; p <.001). " 05/01/2002 - "PURPOSE: This trial was designed to demonstrate equivalence between droloxifene 40 mg/d and tamoxifen 20 mg/d as first-line treatment in pre- and post-menopausal women with ER+ and/or PgR+ advanced breast cancer based on time to disease progression and tumor response. " Order ALL the reference details at left...
4.	T-Cell Leukemia (Leukemia, T Cell) 11/01/1998 - "In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants." Order ALL the reference details at left...
5.	Carcinoma (Carcinomatosis) 08/01/1989 - "Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma." 09/15/1994 - "Therefore, it can be assumed that Droloxifene may represent an important step forward in the treatment of mammary carcinomas in women through its better tolerability and increased efficacy compared with Tamoxifen. " 08/01/1989 - "Droloxifene showed about 20-fold and 3-fold higher affinity to estrogen receptors (ER) in the rat uterus and human ER positive MCF-7 breast carcinoma cells, respectively, than tamoxifen, and was more active in decreasing uterine weight of mature rats and 17 beta-estradiol-treated immature rats. " 01/01/1991 - "Droloxifene differs from tamoxifen in the following ways: it has a more than 10-fold higher binding affinity to the estrogen receptor; it shows lower estrogenic and higher antiestrogenic effects on rat uterus, indicating a higher therapeutic index; it more potently inhibits growth of various human ER-positive mammary carcinoma cell lines; short-term exposures with clinically relevant concentrations of droloxifene produce long-term growth inhibition of human ER-positive cancer cells and are more effective than continuous treatment with tamoxifen; it more effectively reduces S-phases and arrests ER-positive cells in G1-phase of the cell cycle; it antagonizes estrogen independent, growth factor stimulated proliferation of MCF-7 cells with higher efficiency; it blocks estrogen activated c-myc expression better than tamoxifen; it more effectively inhibits growth of various experimental tumors of animal (R 3230, DMBA) and human (T61) origin. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tamoxifen
2.	Estrogen Receptor Modulators (Antiestrogen)
3.	Estrogens (Estrogen)
4.	P-Glycoprotein
5.	Toremifene (Fareston)
6.	trioxifene
7.	4-hydroxytamoxifen
8.	Doxorubicin (Adriamycin)
9.	4-hydroxytoremifene
10.	catechol (pyrocatechol)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Intraperitoneal Injections

Best Treatments:
Research Summary Report
on Breast Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3868 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>